From the pandemic-driven surge in vaccine production to the current boom in GLP-1 therapeutics, CDMOs are playing an ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Emily J. Kirby, MD and the team at Kalos Medical Spa are now offering ShapeScale, a 3D body scanner that tracks weight loss ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Research even suggests it can change users' sense of smell, and other common side effects include diarrhoea, nausea, 'sulphur ...

The average representation of GLP-1 drugs used for weight loss in total annual claims was 10.5% for 2025, an increase over ...

In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records.  Fair Health ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

The supply of GLP-1 drugs like Ozempic has been increasing, but they’re still expensive for most patients. Here are answers ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

The nation's plastic surgeons report their practices are busier than ever as patients want to plump facial features affected by weight loss.